HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology88 papers

Pulmonary hypertension

Last edited: 2 h ago

Overview

Pulmonary hypertension (PH) is a complex hemodynamic disorder characterized by elevated blood pressure in the pulmonary arteries, leading to right ventricular strain and dysfunction. It encompasses a spectrum of clinical conditions, including pulmonary arterial hypertension (PAH), PH associated with left heart disease, lung diseases, chronic thromboembolic disease, and other multifactorial etiologies 6. PH significantly impacts morbidity and mortality, particularly in patients with underlying cardiopulmonary diseases. It affects individuals across various demographics but is more prevalent in middle-aged adults and can be exacerbated by factors such as connective tissue diseases, congenital heart defects, and chronic hypoxia 6. Early recognition and management are crucial in day-to-day practice to mitigate progressive right heart failure and improve survival rates 6.

Pathophysiology

The pathophysiology of PH involves intricate interactions at molecular, cellular, and organ levels. In pulmonary arterial hypertension (PAH), the primary mechanisms include vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, and thrombosis 6. Vascular remodeling leads to medial hypertrophy and intimal thickening of pulmonary arteries, increasing pulmonary vascular resistance and elevating pulmonary arterial pressures 6. Endothelial dysfunction impairs vasodilation and promotes thrombosis, further obstructing blood flow 6. Inflammatory mediators and oxidative stress contribute to these processes, exacerbating vascular stiffness and remodeling 6. Additionally, genetic mutations play a role in hereditary forms of PAH, affecting pathways such as BMPR2 signaling, which regulates vascular homeostasis 6. These pathophysiological cascades collectively result in right ventricular hypertrophy and eventual failure, underscoring the multifaceted nature of PH 6.

Epidemiology

PH exhibits varying incidence and prevalence rates depending on the specific subtype and population studied. Idiopathic PAH affects approximately 15-50 cases per million adults annually, with a higher prevalence in women 6. PH associated with left heart disease is more common, reflecting broader cardiovascular disease trends 6. Geographic and demographic factors also influence prevalence; for instance, chronic thromboembolic PH (CTEPH) may be more prevalent in regions with higher rates of thromboembolic events 6. Over time, there has been an increasing recognition and diagnosis of PH, partly due to improved diagnostic tools and heightened clinical awareness 11. However, significant underdiagnosis remains, particularly in resource-limited settings 55. Risk factors include age, sex (with a female predominance in idiopathic PAH), and comorbidities such as connective tissue diseases, liver disease, and chronic obstructive pulmonary disease (COPD) 6.

Clinical Presentation

Patients with PH often present with nonspecific symptoms initially, including dyspnea on exertion, fatigue, and syncope, which can progress to more severe manifestations like right-sided heart failure 6. Red-flag features include unexplained syncope, peripheral edema, and signs of right heart strain on echocardiography, such as jugular venous distension and tricuspid regurgitation jet velocity ≥ 2.5 m/s 2. Hemoptysis and chest pain may also occur, particularly in advanced stages 6. Early recognition of these symptoms is critical for timely intervention and improved outcomes 6.

Diagnosis

The diagnostic approach to PH involves a combination of clinical evaluation, imaging, and invasive hemodynamic assessments. Key diagnostic criteria and tests include:

  • Clinical Evaluation: Detailed history and physical examination focusing on symptoms and signs of right heart failure.
  • Echocardiography: Essential for initial screening, estimating pulmonary artery pressures (TR jet velocity ≥ 2.5 m/s suggests PH), and assessing right ventricular function 2.
  • Right Heart Catheterization (RHC): Gold standard for definitive diagnosis, confirming mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) ≥ 3 Wood units 6.
  • CT Pulmonary Angiography (CTPA): Useful for ruling out chronic thromboembolic PH (CTEPH) by identifying chronic thromboembolic lesions 39.
  • Differential Diagnosis: Conditions mimicking PH include chronic lung diseases (e.g., COPD, interstitial lung disease), left heart disease, and valvular heart disease. Distinguishing features often involve specific imaging findings and hemodynamic profiles 6.

    • Differential Diagnosis

  • Left Heart Disease: Elevated PCWP (>15 mmHg) differentiates left heart disease from PH.
  • Chronic Lung Diseases: Characteristic imaging findings such as emphysema or interstitial lung changes help distinguish these conditions.
  • Valvular Heart Disease: Echocardiographic evidence of valvular abnormalities aids in differentiation.
  • CTEPH: CTPA showing chronic thromboembolic lesions confirms CTEPH over idiopathic PAH 39.

    • Management

    First-Line Treatment

  • Endothelin Receptor Antagonists (ERAs): Bosentan (62.5 mg twice daily), ambrisentan (5-10 mg daily), or macitentan (10 mg daily) 6.
  • Phosphodiesterase-5 Inhibitors (PDE5i): Sildenafil (20-200 mg three times daily) or tadalafil (2.5-40 mg daily) 6.
  • Prostacyclin Analogues: Epoprostenol (2 ng/kg/min), treprostinil (1-10 ng/kg/min), or selexipase alfa (intravenous or subcutaneous) 6.

    • Second-Line Treatment

  • Adjunct Therapies: Diuretics (e.g., furosemide 20-100 mg daily) for fluid management, anticoagulants (e.g., warfarin INR 2.0-3.0) to prevent thrombosis 6.
  • Soluble Guanylate Cyclase Stimulators: Riociguat (1-2 mg three times daily) for patients not adequately responding to first-line therapies 6.

    • Refractory or Specialist Escalation

  • Oxygen Therapy: Target oxygen saturation 88-92% to avoid vasoconstriction 6.
  • Lung Transplantation: Considered for end-stage disease refractory to medical management 6.
  • Pulmonary Endarterectomy: For CTEPH, surgical intervention may be curative 39.

    • Contraindications:

  • ERAs and PDE5i in pregnancy due to potential teratogenic effects 6.
  • Anticoagulants in active bleeding or high bleeding risk 6.

    • Complications

    Acute Complications

  • Pulmonary Hypertension Crises: Sudden worsening of symptoms requiring immediate medical intervention 7.
  • Right Heart Failure: Manifesting as peripheral edema, ascites, and hepatomegaly 6.

    • Long-Term Complications

  • Cor Pulmonale: Progressive right ventricular dysfunction leading to heart failure 6.
  • Exercise Intolerance: Reduced exercise capacity and quality of life 15.

    • Management Triggers:

  • Close monitoring of biomarkers like NT-proBNP for early signs of heart failure 13.
  • Regular echocardiograms to assess right ventricular function 6.

    • Prognosis & Follow-Up

    The prognosis of PH varies widely depending on the underlying cause and severity at diagnosis. Key prognostic indicators include functional class, exercise capacity (6MWD), and hemodynamic parameters such as PVR 13. Recommended follow-up intervals typically include:

  • Monthly Initial Monitoring: After diagnosis to stabilize treatment.
  • Every 3-6 Months: Regular echocardiograms, functional assessments (6MWD), and biomarker evaluations (NT-proBNP) 13.
  • Annual Comprehensive Evaluation: Including RHC if clinically indicated to reassess hemodynamics 6.

    • Special Populations

    Pediatrics

  • Multidisciplinary Care: Essential for managing complex cases, involving pediatric cardiologists, pulmonologists, and surgeons 22.
  • Specific Therapies: Sildenafil dosing adjusted based on weight (0.5-10 mg/kg/dose, tid) 6.

    • Pregnancy

  • Close Monitoring: High risk of maternal and fetal complications; management requires expert multidisciplinary teams 29.
  • Avoid Certain Medications: ERAs and PDE5i are contraindicated due to potential teratogenic effects 6.

    • Elderly

  • Tailored Treatment: Consider comorbidities and functional status; dose adjustments and careful monitoring are crucial 6.

    • Comorbidities

  • Obstructive Sleep Apnea (OSA): Treatment with CPAP can improve PH symptoms and reduce pulmonary pressures 15.
  • Thiamine Deficiency: Early recognition and supplementation can reverse PH in cases like scurvy or exclusive breastfeeding 923.

    • Key Recommendations

  • Diagnosis: Confirm PH using RHC with mPAP ≥ 25 mmHg, PCWP ≤ 15 mmHg, and PVR ≥ 3 Wood units (Evidence: Strong) 6.
  • Initial Medical Therapy: Initiate with ERAs or PDE5i based on patient characteristics and comorbidities (Evidence: Strong) 6.
  • Monitoring: Regular echocardiograms and functional assessments (6MWD, NT-proBNP) every 3-6 months (Evidence: Moderate) 13.
  • CTEPH Evaluation: Consider CTPA to rule out chronic thromboembolic disease (Evidence: Moderate) 39.
  • Pregnancy Management: Avoid ERAs and PDE5i; multidisciplinary care essential (Evidence: Expert opinion) 6.
  • Exercise Training: Incorporate cardiac rehabilitation programs to improve exercise capacity (Evidence: Moderate) 28.
  • Referral Criteria: Escalate to specialists for refractory cases or those requiring lung transplantation (Evidence: Expert opinion) 6.
  • CPAP for OSA: Recommend CPAP therapy in PH patients with OSA to improve outcomes (Evidence: Moderate) 15.
  • Thiamine Supplementation: Consider in cases of suspected thiamine deficiency (Evidence: Moderate) 923.
  • Hemodynamic Assessment: Use RHC periodically to reassess PVR and guide treatment adjustments (Evidence: Strong) 6.

    • References

    1 Zhou Y, Bai Y, Yang S, Wang S, Ji M, Zhao F et al.. Integrative elucidation of Panax notoginseng 's action against pulmonary hypertension: Network pharmacology and molecular docking insights. Journal of ethnopharmacology 2026. link 2 Mukherjee M, Rudski LG, Addetia K, Afilalo J, D'Alto M, Freed BH et al.. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2025. link 3 Akbari A, Raji H, Islampanah M, Barati S, Davoodian N, Aminizadeh S et al.. Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension. Sleep & breathing = Schlaf & Atmung 2025. link 4 Tang F, Ma Q, Liu Y, Yang X. Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS. Expert opinion on drug safety 2025. link 5 Lu G, Du R, Lu L, Wang Q, Zhang M, Gu X et al.. Macrophage-specific κ-OR knockout exacerbates inflammation in hypoxic pulmonary hypertension. European journal of pharmacology 2025. link 6 Fukumoto Y. Pathophysiology and Treatment of Pulmonary Arterial Hypertension. International journal of molecular sciences 2024. link 7 Bhattacharya S. Emergencies in Pulmonary Hypertension. Cardiology clinics 2024. link 8 Takagi K, Kasai H, Tani H, Sakao S, Sugiura T, Suzuki T. Macitentan Administration for Pulmonary Hypertension Due to β-thalassemia with Multiple Organ Failure. Internal medicine (Tokyo, Japan) 2024. link 9 Satawiriya M, Khongphatthanayothin A, Limsuwan A. Reversible severe pulmonary hypertension related to scurvy in children. BMC cardiovascular disorders 2024. link 10 Wang G, Qin J, Han D. Long-term safety of macitentan in patients with pulmonary hypertension: A meta-analysis of randomised controlled trials. European journal of clinical investigation 2023. link 11 Singh M, Berkey F, Fragin J, Grine K. Pulmonary hypertension: An update of Dx and Tx guidelines. The Journal of family practice 2023. link 12 Lichtblau M, Titz A, Bahrampoori B, Schmiedeskamp M, Ulrich S. What changed after the 2022 guidelines for pulmonary hypertension?. European journal of internal medicine 2023. link 13 Andersen MØ, Diederichsen SZ, Svendsen JH, Carlsen J. Continuous long-term heart rate variability and risk assessment in pulmonary hypertension. Open heart 2023. link 14 Seitler S, Dimopoulos K, Ernst S, Price LC. Medical Emergencies in Pulmonary Hypertension. Seminars in respiratory and critical care medicine 2023. link 15 Sykes AV, Sonners C, Schmickl CN, Raphelson J, Swiatkiewicz I, Roberts E et al.. The Impact of Underlying Obstructive Sleep Apnea Treatment on Exercise Capacity in Patients With Pulmonary Hypertension Undergoing a Cardiac Rehabilitation Program. Journal of cardiopulmonary rehabilitation and prevention 2023. link 16 Sirajuddin A, Mirmomen SM, Henry TS, Kandathil A, Kelly AM, King CS et al.. ACR Appropriateness Criteria® Suspected Pulmonary Hypertension: 2022 Update. Journal of the American College of Radiology : JACR 2022. link 17 Hyder SN, Chatterjee S, Aggarwal V. Percutaneous Treatments for Pulmonary Hypertension: Reviewing the Growing Procedural Role for Interventional Cardiology. Interventional cardiology clinics 2022. link 18 Zhou Y, Liu L, Fan F, Ma W. Echocardiographic Estimated Pulmonary Systolic Pressure and Outcome After Noncardiac-Obstetrics Surgery in Postcapillary Pulmonary Hypertensive Patients. The American journal of cardiology 2022. link 19 Jasińska-Stroschein M, Orszulak-Michalak D. Reporting experimental studies on animals - The problems with translating of outcomes to clinical benefits. Methodological and statistical considerations: The example of pulmonary hypertension. European journal of pharmacology 2021. link 20 Ekici B. Can a patient with pulmonary hypertension travel safely by plane?. Anatolian journal of cardiology 2021. link 21 Gurevich S, Prins KW. The evolving role of interventional cardiology in the treatment of pulmonary hypertension. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2021. link 22 Whalen E, Ely E, Brown A. The role of a multidisciplinary team in a pediatric pulmonary hypertension center. Pediatric pulmonology 2021. link 23 Sastry UMK, M J, Kumar RK, Ghosh S, A P B, Subramanian A et al.. Thiamine-responsive acute severe pulmonary hypertension in exclusively breastfeeding infants: a prospective observational study. Archives of disease in childhood 2021. link 24 Nokes B, Raza H, Malhotra A. Pulmonary hypertension and obstructive sleep apnea. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2020. link 25 Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC et al.. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. Journal of the American College of Cardiology 2020. link 26 Binder ZW, O'Brien SE, Boyle TP, Cabral HJ, Sekhavat S, Pare JR. Novice Physician Ultrasound Evaluation of Pediatric Tricuspid Regurgitant Jet Velocity. The western journal of emergency medicine 2020. link 27 Sallmon H, Moledina S, Albert DC, Beghetti M, Berger RMF, Bonnet D et al.. Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiology in the young 2019. link 28 Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E et al.. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. The European respiratory journal 2019. link 29 Maciejewski T, Darocha T, Kiermasz K, Budziarz B, Duraj P, Szanecki W et al.. Emergency caesarean section delivery and puerperium in a patient with severe idiopathic pulmonary arterial hypertension - a case report. Anaesthesiology intensive therapy 2019. link 30 Butera G, Mansour NB, De Marco F. Emergency trans-catheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4-year-old child. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2019. link 31 Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Otero R, López-Reyes R et al.. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Archivos de bronconeumologia 2018. link 32 Hellenkamp K, Unsöld B, Mushemi-Blake S, Shah AM, Friede T, Hasenfuß G et al.. Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018. link 33 Rehman MB, Garcia R, Christiaens L, Larrieu-Ardilouze E, Howard LS, Nihoyannopoulos P. Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs. International journal of cardiology 2018. link 34 Koestenberger M, Avian A, Sallmon H, Gamillscheg A, Grangl G, Kurath-Koller S et al.. The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network. Echocardiography (Mount Kisco, N.Y.) 2018. link 35 Sirajuddin A, Donnelly EF, Crabtree TP, Henry TS, Iannettoni MD, Johnson GB et al.. ACR Appropriateness Criteria. Journal of the American College of Radiology : JACR 2017. link 36 Sable CA, Ivy DD, Beekman RH, Clayton-Jeter HD, Jenkins KJ, Mahle WT et al.. 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. Journal of the American College of Cardiology 2017. link 37 Fritz JS, Smith KA. The Pulmonary Hypertension Consult: Clinical and Coding Considerations. Chest 2016. link 38 Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart (British Cardiac Society) 2016. link 39 Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK et al.. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015. link 40 Duquette S. A Patient with Pulmonary Hypertension on a Medical-Surgical Unit. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 2015. link 41 Kurzyna M, Araszkiewicz A, Błaszczak P, Grabka M, Hawranek M, Kopeć G et al.. Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions. Kardiologia polska 2015. link 42 Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al.. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). The European respiratory journal 2015. link 43 Chemla D, Lau EM, Papelier Y, Attal P, Hervé P. Pulmonary vascular resistance and compliance relationship in pulmonary hypertension. The European respiratory journal 2015. link 44 Genctoy G, Arikan S, Eldem O. Pulmonary hypertension associates with malnutrition and body composition hemodialysis patients. Renal failure 2015. link 45 Agostoni P, Farina S, Apostolo A, Sciomer S. Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered. European journal of preventive cardiology 2014. link 46 LeVarge BL, Pomerantsev E, Channick RN. Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. The European respiratory journal 2014. link 47 Tanabe N, Taniguchi H, Tsujino I, Sakamaki F, Emoto N, Kimura H et al.. Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. Respiratory investigation 2014. link 48 Ramakrishna H. Pulmonary hypertension in the perioperative period-focus on current and emerging therapies. Recent patents on cardiovascular drug discovery 2014. link 49 Vonk-Noordegraaf A, Westerhof N. Describing right ventricular function. The European respiratory journal 2013. link 50 Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P et al.. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. Internal medicine journal 2013. link 51 Asakura T, Kodera S, Kanda J, Ikeda M. Thiamine-responsive pulmonary hypertension. BMJ case reports 2013. link 52 Haja Mydin H, Fisher AJ. Pulmonary hypertension and lung transplantation: Thorax publication activity review 2008-2010. Thorax 2012. link 53 Scheidl SJ, Englisch C, Kovacs G, Reichenberger F, Schulz R, Breithecker A et al.. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. The European respiratory journal 2012. link 54 Dalton B, McNeil K, Keogh A, Williams T, Proudman S, Gabbay E et al.. Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. International journal of clinical practice 2012. link 55 Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al.. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012. link 56 Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH et al.. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. International journal of cardiology 2011. link70489-2) 57 Serag AR, Hazaa SM, Afifi IK, Ghoname NF, Serag AR. Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2010. link 58 . Developing new guidelines for the diagnosis and treatment of pulmonary hypertension. European heart journal 2009. link 59 Koch DG, Caplan M, Reuben A. Pulmonary hypertension after liver transplantation: case presentation and review of the literature. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2009. link 60 Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. The European respiratory journal 2008. link 61 Cha CY, Earm KH, Youm JB, Baek EB, Kim SJ, Earm YE. Electrophysiological modelling of pulmonary artery smooth muscle cells in the rabbits--special consideration to the generation of hypoxic pulmonary vasoconstriction. Progress in biophysics and molecular biology 2008. link 62 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. The European respiratory journal 2008. link 63 Nathan AT, Marino BS, Hanna B, Nicolson SC. Novel use of dexmedetomidine in a patient with pulmonary hypertension. Paediatric anaesthesia 2008. link 64 Coelho LS, Hueb JC, Minicucci MF, Azevedo PS, Paiva SA, Zornoff LA. Thiamin deficiency as a cause of reversible cor pulmonale. Arquivos brasileiros de cardiologia 2008. link 65 Zhang Y, Qui Y, Zhu J, Gao D. Pulmonary hypertension associated with autoimmune hemolytic anemia: a case report. International journal of cardiology 2007. link 66 Park JH, Lee JH, Jeong JO, Seong IW, Choi SW. Thiamine deficiency as a rare cause of reversible severe pulmonary hypertension. International journal of cardiology 2007. link 67 Paolini R, Armigliato M, Zamboni S. Pulmonary hypertension and systemic diseases. Current drug targets. Inflammation and allergy 2004. link 68 Lemire EG, Petch P. Short stature, pulmonary hypertension, sclerodactyly-like involvement and dysmorphic appearance: a newly described syndrome?. Clinical dysmorphology 2004. link 69 Patel MS, Taylor GP, Bharya S, Al-Sanna'a N, Adatia I, Chitayat D et al.. Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. American journal of medical genetics. Part A 2004. link 70 Shekerdemian LS, Penny DJ, Ryhammer PK, Reader JA, Ravn HB. Endothelin-A receptor blockade and inhaled nitric oxide in a porcine model of meconium aspiration syndrome. Pediatric research 2004. link 71 Sims JM. What's new in pulmonary artery hypertension. Dimensions of critical care nursing : DCCN 2003. link 72 Raas-Rothschild A, Ergaz-Schaltiel Z, Bar-Ziv J, Rein AJ. Cardiovascular abnormalities associated with the Stuve-Wiedemann syndrome. American journal of medical genetics. Part A 2003. link 73 Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiological research 2000. link 74 Ceccarelli P, Bigatello LM, Hess D, Kwo J, Melendez L, Hurford WE. Inhaled nitric oxide delivery by anesthesia machines. Anesthesia and analgesia 2000. link 75 Palevsky HI, Gurughagavatula I. Pulmonary hypertension in collagen vascular disease. Comprehensive therapy 1999. link 76 Nakayama M, Kondo U, Murray PA. Pulmonary vasodilator response to adenosine triphosphate-sensitive potassium channel activation is attenuated during desflurane but preserved during sevoflurane anesthesia compared with the conscious state. Anesthesiology 1998. link 77 Espinosa RE, Edwards WD, Rosenow EC, Schaff HV. Idiopathic pulmonary hilar fibrosis: an unusual cause of pulmonary hypertension. Mayo Clinic proceedings 1993. link60636-3) 78 Vandiviere HM. Pulmonary hypertension and cor pulmonale. Southern medical journal 1993. link 79 Weissman NJ, Fuster V. Diagnosis of pulmonary artery hypertension. Heart disease and stroke : a journal for primary care physicians 1992. link 80 Laor T, Deluca SA. Pulmonary hypertension. American family physician 1989. link 81 Beck R, Killeen VB, Short B. Term abdominal pregnancy, meconium aspiration, and extracorporeal membrane oxygenation. Clinical pediatrics 1987. link 82 Porterfield JK, Pyeritz RE, Traill TA. Pulmonary hypertension and interstitial fibrosis in von Recklinghausen neurofibromatosis. American journal of medical genetics 1986. link 83 Barnes PJ, Cadieux A, Carstairs JR, Greenberg B, Polak JM, Rhoden K. Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. British journal of pharmacology 1986. link 84 Canny GJ, Arbus GS, Wilson GJ, Newth CJ. Fatal pulmonary hypertension following renal transplantation. British journal of diseases of the chest 1985. link 85 Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest 1985. link 86 Bernthal AC, Eybel CE, Payne JA. Primary pulmonary hypertension after portocaval shunt. Journal of clinical gastroenterology 1983. link 87 Romanoff H, Manny J, Aviad I. Pulmonary varices. Report of two cases and review of the literature. Chest 1976. link 88 Heath D, Scott O, Lynch J. Pulmonary veno-occlusive disease. Thorax 1971. link

    Original source

    1. [1]
      Integrative elucidation of Panax notoginseng 's action against pulmonary hypertension: Network pharmacology and molecular docking insights. — Zhou Y, Bai Y, Yang S, Wang S, Ji M, Zhao F et al. Journal of ethnopharmacology (2026)
    2. [2]
      Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. — Mukherjee M, Rudski LG, Addetia K, Afilalo J, D'Alto M, Freed BH et al. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2025)
    3. [3]
      Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension. — Akbari A, Raji H, Islampanah M, Barati S, Davoodian N, Aminizadeh S et al. Sleep & breathing = Schlaf & Atmung (2025)
    4. [4]
      Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS. — Tang F, Ma Q, Liu Y, Yang X Expert opinion on drug safety (2025)
    5. [5]
      Macrophage-specific κ-OR knockout exacerbates inflammation in hypoxic pulmonary hypertension. — Lu G, Du R, Lu L, Wang Q, Zhang M, Gu X et al. European journal of pharmacology (2025)
    6. [6]
      Pathophysiology and Treatment of Pulmonary Arterial Hypertension. — Fukumoto Y International journal of molecular sciences (2024)
    7. [7]
      Emergencies in Pulmonary Hypertension. — Bhattacharya S Cardiology clinics (2024)
    8. [8]
      Macitentan Administration for Pulmonary Hypertension Due to β-thalassemia with Multiple Organ Failure. — Takagi K, Kasai H, Tani H, Sakao S, Sugiura T, Suzuki T Internal medicine (Tokyo, Japan) (2024)
    9. [9]
      Reversible severe pulmonary hypertension related to scurvy in children. — Satawiriya M, Khongphatthanayothin A, Limsuwan A BMC cardiovascular disorders (2024)
    10. [10]
      Long-term safety of macitentan in patients with pulmonary hypertension: A meta-analysis of randomised controlled trials. — Wang G, Qin J, Han D European journal of clinical investigation (2023)
    11. [11]
      Pulmonary hypertension: An update of Dx and Tx guidelines. — Singh M, Berkey F, Fragin J, Grine K The Journal of family practice (2023)
    12. [12]
      What changed after the 2022 guidelines for pulmonary hypertension? — Lichtblau M, Titz A, Bahrampoori B, Schmiedeskamp M, Ulrich S European journal of internal medicine (2023)
    13. [13]
      Continuous long-term heart rate variability and risk assessment in pulmonary hypertension. — Andersen MØ, Diederichsen SZ, Svendsen JH, Carlsen J Open heart (2023)
    14. [14]
      Medical Emergencies in Pulmonary Hypertension. — Seitler S, Dimopoulos K, Ernst S, Price LC Seminars in respiratory and critical care medicine (2023)
    15. [15]
      The Impact of Underlying Obstructive Sleep Apnea Treatment on Exercise Capacity in Patients With Pulmonary Hypertension Undergoing a Cardiac Rehabilitation Program. — Sykes AV, Sonners C, Schmickl CN, Raphelson J, Swiatkiewicz I, Roberts E et al. Journal of cardiopulmonary rehabilitation and prevention (2023)
    16. [16]
      ACR Appropriateness Criteria® Suspected Pulmonary Hypertension: 2022 Update. — Sirajuddin A, Mirmomen SM, Henry TS, Kandathil A, Kelly AM, King CS et al. Journal of the American College of Radiology : JACR (2022)
    17. [17]
      Percutaneous Treatments for Pulmonary Hypertension: Reviewing the Growing Procedural Role for Interventional Cardiology. — Hyder SN, Chatterjee S, Aggarwal V Interventional cardiology clinics (2022)
    18. [18]
      Echocardiographic Estimated Pulmonary Systolic Pressure and Outcome After Noncardiac-Obstetrics Surgery in Postcapillary Pulmonary Hypertensive Patients. — Zhou Y, Liu L, Fan F, Ma W The American journal of cardiology (2022)
    19. [19]
      Reporting experimental studies on animals - The problems with translating of outcomes to clinical benefits. Methodological and statistical considerations: The example of pulmonary hypertension. — Jasińska-Stroschein M, Orszulak-Michalak D European journal of pharmacology (2021)
    20. [20]
      Can a patient with pulmonary hypertension travel safely by plane? — Ekici B Anatolian journal of cardiology (2021)
    21. [21]
      The evolving role of interventional cardiology in the treatment of pulmonary hypertension. — Gurevich S, Prins KW Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
    22. [22]
      The role of a multidisciplinary team in a pediatric pulmonary hypertension center. — Whalen E, Ely E, Brown A Pediatric pulmonology (2021)
    23. [23]
      Thiamine-responsive acute severe pulmonary hypertension in exclusively breastfeeding infants: a prospective observational study. — Sastry UMK, M J, Kumar RK, Ghosh S, A P B, Subramanian A et al. Archives of disease in childhood (2021)
    24. [24]
      Pulmonary hypertension and obstructive sleep apnea. — Nokes B, Raza H, Malhotra A Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2020)
    25. [25]
      Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. — Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC et al. Journal of the American College of Cardiology (2020)
    26. [26]
      Novice Physician Ultrasound Evaluation of Pediatric Tricuspid Regurgitant Jet Velocity. — Binder ZW, O'Brien SE, Boyle TP, Cabral HJ, Sekhavat S, Pare JR The western journal of emergency medicine (2020)
    27. [27]
      Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. — Sallmon H, Moledina S, Albert DC, Beghetti M, Berger RMF, Bonnet D et al. Cardiology in the young (2019)
    28. [28]
      ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. — Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E et al. The European respiratory journal (2019)
    29. [29]
      Emergency caesarean section delivery and puerperium in a patient with severe idiopathic pulmonary arterial hypertension - a case report. — Maciejewski T, Darocha T, Kiermasz K, Budziarz B, Duraj P, Szanecki W et al. Anaesthesiology intensive therapy (2019)
    30. [30]
      Emergency trans-catheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4-year-old child. — Butera G, Mansour NB, De Marco F Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
    31. [31]
      Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. — Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Otero R, López-Reyes R et al. Archivos de bronconeumologia (2018)
    32. [32]
      Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. — Hellenkamp K, Unsöld B, Mushemi-Blake S, Shah AM, Friede T, Hasenfuß G et al. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2018)
    33. [33]
      Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs. — Rehman MB, Garcia R, Christiaens L, Larrieu-Ardilouze E, Howard LS, Nihoyannopoulos P International journal of cardiology (2018)
    34. [34]
      The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network. — Koestenberger M, Avian A, Sallmon H, Gamillscheg A, Grangl G, Kurath-Koller S et al. Echocardiography (Mount Kisco, N.Y.) (2018)
    35. [35]
      ACR Appropriateness Criteria — Sirajuddin A, Donnelly EF, Crabtree TP, Henry TS, Iannettoni MD, Johnson GB et al. Journal of the American College of Radiology : JACR (2017)
    36. [36]
      2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. — Sable CA, Ivy DD, Beekman RH, Clayton-Jeter HD, Jenkins KJ, Mahle WT et al. Journal of the American College of Cardiology (2017)
    37. [37]
      The Pulmonary Hypertension Consult: Clinical and Coding Considerations. — Fritz JS, Smith KA Chest (2016)
    38. [38]
      Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. — Apitz C, Hansmann G, Schranz D Heart (British Cardiac Society) (2016)
    39. [39]
      Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. — Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK et al. Circulation (2015)
    40. [40]
      A Patient with Pulmonary Hypertension on a Medical-Surgical Unit. — Duquette S Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses (2015)
    41. [41]
      Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions. — Kurzyna M, Araszkiewicz A, Błaszczak P, Grabka M, Hawranek M, Kopeć G et al. Kardiologia polska (2015)
    42. [42]
      2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). — Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. The European respiratory journal (2015)
    43. [43]
      Pulmonary vascular resistance and compliance relationship in pulmonary hypertension. — Chemla D, Lau EM, Papelier Y, Attal P, Hervé P The European respiratory journal (2015)
    44. [44]
      Pulmonary hypertension associates with malnutrition and body composition hemodialysis patients. — Genctoy G, Arikan S, Eldem O Renal failure (2015)
    45. [45]
      Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered. — Agostoni P, Farina S, Apostolo A, Sciomer S European journal of preventive cardiology (2014)
    46. [46]
      Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. — LeVarge BL, Pomerantsev E, Channick RN The European respiratory journal (2014)
    47. [47]
      Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. — Tanabe N, Taniguchi H, Tsujino I, Sakamaki F, Emoto N, Kimura H et al. Respiratory investigation (2014)
    48. [48]
      Pulmonary hypertension in the perioperative period-focus on current and emerging therapies. — Ramakrishna H Recent patents on cardiovascular drug discovery (2014)
    49. [49]
      Describing right ventricular function. — Vonk-Noordegraaf A, Westerhof N The European respiratory journal (2013)
    50. [50]
      Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. — Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P et al. Internal medicine journal (2013)
    51. [51]
      Thiamine-responsive pulmonary hypertension. — Asakura T, Kodera S, Kanda J, Ikeda M BMJ case reports (2013)
    52. [52]
      Pulmonary hypertension and lung transplantation: Thorax publication activity review 2008-2010. — Haja Mydin H, Fisher AJ Thorax (2012)
    53. [53]
      Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. — Scheidl SJ, Englisch C, Kovacs G, Reichenberger F, Schulz R, Breithecker A et al. The European respiratory journal (2012)
    54. [54]
      Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. — Dalton B, McNeil K, Keogh A, Williams T, Proudman S, Gabbay E et al. International journal of clinical practice (2012)
    55. [55]
      Pulmonary arterial hypertension in patients treated by dasatinib. — Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Circulation (2012)
    56. [56]
      Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. — Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH et al. International journal of cardiology (2011)
    57. [57]
      Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions. — Serag AR, Hazaa SM, Afifi IK, Ghoname NF, Serag AR European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2010)
    58. [58]
      Developing new guidelines for the diagnosis and treatment of pulmonary hypertension. European heart journal (2009)
    59. [59]
      Pulmonary hypertension after liver transplantation: case presentation and review of the literature. — Koch DG, Caplan M, Reuben A Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2009)
    60. [60]
      Biomarkers in pulmonary hypertension. — Warwick G, Thomas PS, Yates DH The European respiratory journal (2008)
    61. [61]
      Electrophysiological modelling of pulmonary artery smooth muscle cells in the rabbits--special consideration to the generation of hypoxic pulmonary vasoconstriction. — Cha CY, Earm KH, Youm JB, Baek EB, Kim SJ, Earm YE Progress in biophysics and molecular biology (2008)
    62. [62]
      Clinical predictors of pulmonary hypertension in sarcoidosis. — Bourbonnais JM, Samavati L The European respiratory journal (2008)
    63. [63]
      Novel use of dexmedetomidine in a patient with pulmonary hypertension. — Nathan AT, Marino BS, Hanna B, Nicolson SC Paediatric anaesthesia (2008)
    64. [64]
      Thiamin deficiency as a cause of reversible cor pulmonale. — Coelho LS, Hueb JC, Minicucci MF, Azevedo PS, Paiva SA, Zornoff LA Arquivos brasileiros de cardiologia (2008)
    65. [65]
      Pulmonary hypertension associated with autoimmune hemolytic anemia: a case report. — Zhang Y, Qui Y, Zhu J, Gao D International journal of cardiology (2007)
    66. [66]
      Thiamine deficiency as a rare cause of reversible severe pulmonary hypertension. — Park JH, Lee JH, Jeong JO, Seong IW, Choi SW International journal of cardiology (2007)
    67. [67]
      Pulmonary hypertension and systemic diseases. — Paolini R, Armigliato M, Zamboni S Current drug targets. Inflammation and allergy (2004)
    68. [68]
      Short stature, pulmonary hypertension, sclerodactyly-like involvement and dysmorphic appearance: a newly described syndrome? — Lemire EG, Petch P Clinical dysmorphology (2004)
    69. [69]
      Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. — Patel MS, Taylor GP, Bharya S, Al-Sanna'a N, Adatia I, Chitayat D et al. American journal of medical genetics. Part A (2004)
    70. [70]
      Endothelin-A receptor blockade and inhaled nitric oxide in a porcine model of meconium aspiration syndrome. — Shekerdemian LS, Penny DJ, Ryhammer PK, Reader JA, Ravn HB Pediatric research (2004)
    71. [71]
      What's new in pulmonary artery hypertension. — Sims JM Dimensions of critical care nursing : DCCN (2003)
    72. [72]
      Cardiovascular abnormalities associated with the Stuve-Wiedemann syndrome. — Raas-Rothschild A, Ergaz-Schaltiel Z, Bar-Ziv J, Rein AJ American journal of medical genetics. Part A (2003)
    73. [73]
      Changing concepts of the pulmonary plexiform lesion. — Fishman AP Physiological research (2000)
    74. [74]
      Inhaled nitric oxide delivery by anesthesia machines. — Ceccarelli P, Bigatello LM, Hess D, Kwo J, Melendez L, Hurford WE Anesthesia and analgesia (2000)
    75. [75]
      Pulmonary hypertension in collagen vascular disease. — Palevsky HI, Gurughagavatula I Comprehensive therapy (1999)
    76. [76]
      Pulmonary vasodilator response to adenosine triphosphate-sensitive potassium channel activation is attenuated during desflurane but preserved during sevoflurane anesthesia compared with the conscious state. — Nakayama M, Kondo U, Murray PA Anesthesiology (1998)
    77. [77]
      Idiopathic pulmonary hilar fibrosis: an unusual cause of pulmonary hypertension. — Espinosa RE, Edwards WD, Rosenow EC, Schaff HV Mayo Clinic proceedings (1993)
    78. [78]
      Pulmonary hypertension and cor pulmonale. — Vandiviere HM Southern medical journal (1993)
    79. [79]
      Diagnosis of pulmonary artery hypertension. — Weissman NJ, Fuster V Heart disease and stroke : a journal for primary care physicians (1992)
    80. [80]
      Pulmonary hypertension. — Laor T, Deluca SA American family physician (1989)
    81. [81]
      Term abdominal pregnancy, meconium aspiration, and extracorporeal membrane oxygenation. — Beck R, Killeen VB, Short B Clinical pediatrics (1987)
    82. [82]
      Pulmonary hypertension and interstitial fibrosis in von Recklinghausen neurofibromatosis. — Porterfield JK, Pyeritz RE, Traill TA American journal of medical genetics (1986)
    83. [83]
      Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. — Barnes PJ, Cadieux A, Carstairs JR, Greenberg B, Polak JM, Rhoden K British journal of pharmacology (1986)
    84. [84]
      Fatal pulmonary hypertension following renal transplantation. — Canny GJ, Arbus GS, Wilson GJ, Newth CJ British journal of diseases of the chest (1985)
    85. [85]
      Hypotension and sinus arrest with nifedipine in pulmonary hypertension. — Aromatorio GJ, Uretsky BF, Reddy PS Chest (1985)
    86. [86]
      Primary pulmonary hypertension after portocaval shunt. — Bernthal AC, Eybel CE, Payne JA Journal of clinical gastroenterology (1983)
    87. [87]
      Pulmonary varices. Report of two cases and review of the literature. — Romanoff H, Manny J, Aviad I Chest (1976)
    88. [88]
      Pulmonary veno-occlusive disease. — Heath D, Scott O, Lynch J Thorax (1971)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG